Risk assessment for peri- and post-menopausal women taking food supplements containing isolated isoflavones

EFSA Journal

Volumn 13, Issue 10, 2015, Pages

[No Author Info available]

Author keywords

food supplements; isoflavones; mammary gland; phytoestrogens; systematic review; thyroid; uterus

Indexed keywords

EID: 85069896211     PISSN: None     EISSN: 18314732     Source Type: Journal    
DOI: 10.2903/j.efsa.2015.4246     Document Type: Article

References (329)

1. Abe T, 1999. Infantile leukemia and soybeans-a hypothesis. Leukemia, 13, 317–320.
2. Adaikan PG, Srilatha B and Wheat AJ, 2009. Efficacy of red clover isoflavones in the menopausal rabbit model. Fertility and Sterility, 92, 2008–2013. doi: 10.1016/j.fertnstert.2008.09.020.
3. AFFSA (Agence française de sécurité sanitaire des aliments), 2005, online. Sécurité et bénéfices des phyto-estrogènes apportés par l'alimentation-Recommandations. Mar 2005. Available online: https://www.anses.fr/fr/system/files/NUT-Ra-Phytoestrogenes.pdf.
4. Akiyama T, Ishida J, Nakagawa S, Ogawara H, Watanabe S, Itoh N, Shibuya M and Fukami Y, 1987. Genistein, a specific inhibitor of tyrosine-specific protein kinases. Journal of Biological Chemistry, 262, 5592–5595.
5. Alekel DL, Genschel U, Koehler KJ, Hofmann H, Van Loan MD, Beer BS, Hanson LN, Peterson CT and Kurzer MS, 2015. Soy Isoflavones for Reducing Bone Loss Study: effects of a 3-year trial on hormones, adverse events, and endometrial thickness in postmenopausal women. Menopause, 22, 185–197. doi: 10.1097/GME.0000000000000280.
6. Allred CD, Allred KF, Ju YH, Virant SM and Helferich WG, 2001a. Soy diets containing varying amounts of genistein stimulate growth of estrogen-dependent (MCF-7) tumors in a dose-dependent manner. Cancer Research 2001 61, 5045–5050.
7. Allred CD, Ju YH, Allred KF, Chang J and Helferich WG, 2001b. Dietary genistin stimulates growth of estrogen-dependent breast cancer tumors similar to that observed with genistein. Carcinogenesis, 22, 1667–1673.
8. Allred CD, Twaddle NC, Allred KF, Goeppinger TS, Churchwell MI, Ju YH, Helferich WG and Doerge DR, 2005. Soy processing affects metabolism and disposition of dietary isoflavones in ovariectomized Balb/c mice. Journal of Agricultural and Food Chemistry, 53, 8542–8550. doi: 10.1021/jf051246w.
9. Almeida IM, Rodrigues F, Sarmento B, Alves RC and Oliveira MB, 2015. Isoflavones in food supplements: chemical profile, label accordance and permeability study in Caco-2 cells. Food and Function, 6, 938–946. doi: 10.1039/c4fo01144a.
10. Alves DL, Lima SM, Da Silva CR, Galvão MA, Shanaider A, De Almeida Prado RA and Aoki T, 2008. Effects of Trifolium pratense and Cimicifuga racemosa on the endometrium of Wistar rats. Maturitas, 61, 364–370. doi: 10.1016/j.maturitas.2008.08.006.
11. Andrade JE, Twaddle NC, Helferich WG and Doerge DR, 2010. Absolute bioavailability of isoflavones from soy protein isolate-containing food in female Balb/c mice. Journal of Agricultural and Food Chemistry, 58, 4529–4536. doi: 10.1021/jf9039843.
12. Andres S, Hansen U, Niemann B, Palavinskas R and Lampen A, 2015. Determination of the isoflavone composition and estrogenic activity of commercial dietary supplements based on soy or red clover. Food and Function, 6, 2017–2025. doi: 10.1039/c5fo00308c.
13. ANSES (French Agency for Food, Environmental and Occupational Health & Safety), 2011, online. Second French Total Diet Study (TDS 2) Report 1: Inorganic contaminants, minerals, persistent organic pollutants, mycotoxins and phytoestrogens. Available online: https://www.anses.fr/en/system/files/PASER2006sa0361Ra1EN.pdf.
14. Atkinson C, Warren RM, Sala E, Dowsett M, Dunning AM, Healey CS, Runswick S, Day NE and Bingham SA, 2004. Red-clover-derived isoflavones and mammographic breast density: a double-blind, randomized, placebo-controlled trial [ISRCTN42940165]. Breast Cancer Research, 6, R170–179.
15. Austin CA, Patel S, Ono K, Nakane H and Fisher LM, 1992. Site-specific DNA cleavage by mammalian DNA topoisomerase II induced by novel flavone and catechin derivatives. The Biochemical Journal, 282, 883–889.
16. Baechler SA, Schroeter A, Walker J, Aichinger G and Marko D, 2014. Oxidative metabolism enhances the cytotoxic and genotoxic properties of the soy isoflavone daidzein. Molecular Nutrition and Food Research, 58, 1269–1281. doi: 10.1002/mnfr.201300531.
17. Baeza I, Alvarado C, Alvarez P, Salazar V, Castillo C, Ariznavarreta C, Fdez-Tresguerres JA and De la Fuente M, 2009. Improvement of leucocyte functions in ovariectomised aged rats after treatment with growth hormone, melatonin, oestrogens or phyto-oestrogens. Journal of Reproductive Immunology, 80, 70–79. doi: 10.1016/j.jri.2009.02.002.
18. Bahr JM, Nakai M, Rivera A, Walsh J, Evans GL, Lotinun S, Turner RT, Black M and Jeffery EH, 2005. Dietary soy protein and isoflavones: minimal beneficial effects on bone and no effect on the reproductive tract of sexually mature ovariectomized Sprague-Dawley rats. Menopause, 12, 165–173.
19. Bayer T, Colnot T and Dekant W, 2001. Disposition and biotransformation of the estrogenic isoflavone daidzein in rats. Toxicological Sciences, 62, 205–211.
20. Bell DSH and Ovalle F, 2001. Use of soy protein supplement and resultant need for increased dose of levothyroxine. Endocrine Practice, 7, 193–194.
21. Belloque J, García MC, Torre M and Marina ML, 2002. Analysis of soyabean proteins in meat products: a review. Critical Reviews in Food Science and Nutrition, 42, 507–532.
22. Bennetts HW, Uuderwood EJ and Shier FL, 1946. A specific breeding problem of sheep on subterranean clover pastures in Western Australia. Australian Veterinary Journal, 22, 2–12.
23. BfR (Bundesinstitut für Risikobewertung), 2007, online. Updated BfR Expert Opinion No 039/2007. Available online: http://www.bfr.bund.de/cm/349/isolated_isoflavones_are_not_without_risk.pdf.
24. Bitto A, Altavilla D, Bonaiuto A, Polito F, Minutoli L, Di Stefano V, Giuliani D, Guarini S, Arcoraci V and Squadrito F, 2009. Effects of aglycone genistein in a rat experimental model of postmenopausal metabolic syndrome. Journal of Endocrinology, 200, 367–376. doi: 10.1677/JOE-08-0206.
25. Bitto A, Polito F, Atteritano M, Altavilla D, Mazzaferro S, Marini H, Adamo EB, D'Anna R, Granese R, Corrado F, Russo S, Minutoli L and Squadrito F, 2010. Genistein aglycone does not affect thyroid function: results from a three-year, randomized, double-blind, placebo-controlled trial. Journal of Clinical Endocrinology and Metabolism, 95, 3067–3072. doi: 10.1210/jc.2009-2779.
26. Boker LK, Van der Schouw YT, De Kleijn MJ, Jacques PF, Grobbee DE and Peeters PH, 2002. Intake of dietary phytoestrogens by Dutch women. Journal of Nutrition, 132, 1319–1328.
27. Bolca S, Urpi-Sarda M, Blondeel P, Roche N, Vanhaecke L, Possemiers S, Al-Maharik N, Botting N, De Keukeleire D, Bracke M, Heyerick A, Manach C and Depypere H, 2010. Disposition of soy isoflavones in normal human breast tissue. American Journal of Clinical Nutrition, 91, 976–984. doi: 10.3945/ajcn.2009.28854.
28. Boniglia C, Carratù B, Gargiulo R, Giammarioli S, Mosca M and Sanzini E, 2009. Content of phytoestrogens in soy-based dietary supplements. Food Chemistry, 115, 1389–1392. doi: 10.1016/j.foodchem.2009.01.062.
29. Boobis AR, Cohen SM, Dellarco V, McGregor D, Meek ME, Vickers C, Willcocks D and Farland W, 2006. IPCS framework for analyzing the relevance of a cancer mode of action for humans. Critical Reviews in Toxicology, 36, 781–792.
30. Boobis AR, Doe JE, Heinrich-Hirsch B, Meek ME, Munn S, Ruchirawat M, Schlatter J, Seed J and Vickers C, 2008. IPCS framework for analyzing the relevance of a noncancer mode of action for humans. Critical Reviews in Toxicology, 38, 87–96. doi: 10.1080/10408440701749421.
31. Boucher BA, Cotterchio M, Anderson LN, Kreiger N, Kirsh VA and Thompson LU, 2013. Use of isoflavone supplements is associated with reduced postmenopausal breast cancer risk. International Journal of Cancer, 132, 1439–1450. doi: 10.1002/ijc.27769.
32. Boyd NF, 2013. Mammographic density and risk of breast cancer. American Society of Clinical Oncology Educational Book. doi: 10.1200/EdBook_AM.2013.33.e57.
33. Braden AWH, Southcott WH and Moule GR, 1964. Assessment of oestrogenic activity of pastures by means of increase of teat length in sheep. Australian Journal of Agricultural Research 15, 142–152.
34. Brasky TM, Lampe JW, Potter JD, Patterson RE and White E, 2010. Specialty supplements and breast cancer risk in the VITamins And Lifestyle (VITAL) Cohort. Cancer Epidemiology, Biomarkers and Prevention, 19, 1696–1708. doi: 10.1158/1055-9965.EPI-10-0318.
35. Braune A, Maul R, Schebb NH, Kulling SE and Blaut M, 2010. The red clover isoflavone irilone is largely resistant to degradation by the human gut microbiota. Molecular Nutrition and Food Research, 54, 929–938. doi: 10.1002/mnfr.200900233.
36. Breinholt V, Hossaini A, Svendsen GW, Brouwer C and Nielsen E, 2000. Estrogenic activity of flavonoids in mice. The importance of estrogen receptor distribution, metabolism and bioavailability. Food and Chemical Toxicology, 38, 555–564.
37. Breitman PL, Fonseca D, Cheung AM and Ward WE, 2003. Isoflavones with supplemental calcium provide greater protection against the loss of bone mass and strength after ovariectomy compared to isoflavones alone. Bone, 33, 597–605.
38. Bruce B, Messina M and Spiller GA, 2003. Isoflavone supplements do not affect thyroid function in iodine-replete postmenopausal women. Journal of Medicinal Food, 6, 309–316.
39. Burdette JE, Liu J, Lantvit D, Lim E, Booth N, Bhat KP, Hedayat S, Van Breemen RB, Constantinou AI, Pezzuto JM, Farnsworth NR and Bolton JL, 2002. Trifolium pratense (red clover) exhibits estrogenic effects in vivo in ovariectomized Sprague-Dawley rats. Journal of Nutrition, 132, 27–30.
40. Busby MG, Jeffcoat AR, Bloedon LT, Koch MA, Black T, Dix KJ, Heizer WD, Thomas BF, Hill JM, Crowell JA and Zeisel SH, 2002. Clinical characteristics and pharmacokinetics of purified soy isoflavones: single-dose administration to healthy men. The American Journal of Clinical Nutrition, 75, 126–136.
41. Carbonel AA, Baracat MC, Simões RS, Simões MJ, Baracat EC and Soares JM Jr, 2011a. The soybean concentrated extract proliferates the vagina of adult rats. Menopause, 18, 93–101. doi: 10.1097/gme.0b013e3181e5ee25.
42. Carbonel AA, Simões RS, Santos RH, Baracat MC, Simões Mde J, Baracat EC and Soares Júnior JM, 2011b. Effects of high-dose isoflavones on rat uterus. Revista da Associação Medica Brasileira, 2011, 57, 534–539.
43. Carbonel AA, Calió ML, Santos MA, Bertoncini CR, Sasso Gda S, Simões RS, Simões MJ and Soares JM Jr., 2015. Soybean isoflavones attenuate the expression of genes related to endometrial cancer risk. Climacteric, 18, 389–398. doi: 10.3109/13697137.2014.964671.
44. Carmignani LO, Pedro AO, Costa-Paiva LH and Pinto-Neto AM, 2010. The effect of dietary soy supplementation compared to estrogen and placebo on menopausal symptoms: a randomized controlled trial. Maturitas, 67, 262–269. doi:10.1016/j.maturitas.2010.07.007.
45. Carmona-Sánchez E, Cuadros López JL, Cuadros Celorrio ÁM, Pérez-Roncero G, González Ramírez AR and Fernández Alonso AM, 2013. Assessment of mammographic density in postmenopausal women during long term hormone replacement therapy. Gynecological Endocrinology, 29, 1067–1070.
46. Carreau C, Flouriot G, Bennetau-Pelissero C and Potier M, 2009. Respective contribution exerted by AF-1 and AF-2 transactivation functions in estrogen receptor alpha induced transcriptional activity by isoflavones and equol: consequence on breast cancer cell proliferation. Molecular Nutrition and Food Research, 53, 652–658.
47. Castillo C, Salazar V, Ariznavarreta C, Vara E and Tresguerres JA, 2006. Effect of isoflavone administration on age-related hepatocyte changes in old ovariectomized female Wistar rats. Phytomedicine, 13, 468–476.
48. Catania MA, Crupi A, Firenzuoli F, Parisi A, Sturiale A, Squadrito F, Caputi AP and Calapai G, 2002. Oral administration of a soy extract improves endothelial dysfunction in ovariectomized rats. Planta Medica, 68, 1142–1144.
49. Chan SG, Murphy PA, Ho SC, Kreiger N, Darlington G, So EK and Chong PY, 2009. Isoflavonoid Content of Hong Kong Soy Foods. Journal of Agricultural and Food Chemistry, 57, 5386–53890. doi: 10.1021/jf803870k.
50. Chandrareddy A, Muneyyirci-Delale O, McFarlane SI and Murad OM, 2008. Adverse effects of phytoestrogens on reproductive health: a report of three cases. Complementary Therapies in Clinical Practice, 14, 132–135. doi: 10.1016/j.ctcp.2008.01.002.
51. Chang HC, Churchwell MI, Delclos KB, Newbold RR and Doerge DR, 2000. Mass spectrometric determination of Genistein tissue distribution in diet-exposed Sprague-Dawley rats. The Journal of Nutrition, 130, 1963–1970.
52. Chen HL, Hong L-T, Lee JK and Huang C-J, 2009. The bone-protective effect of a Taiwanese yam (Dioscorea alata L. cv. Tainung No. 2) in ovariectomised female BALB/C mice. Journal of the Science of Food and Agriculture, 89, 517–522. doi: 10.1002/jsfa.3489.
53. Cheng G, Wilczek B, Warner M, Gustafsson JA and Landgren BM, 2007. Isoflavone treatment for acute menopausal symptoms. Menopause, 14, 468–473.
54. Chilibeck PD, Vatanparast H, Pierson R, Case A, Olatunbosun O, Whiting SJ, Beck TJ, Pahwa P and Biem HJ, 2013. Effect of exercise training combined with isoflavone supplementation on bone and lipids in postmenopausal women: a randomized clinical trial. Journal of Bone and Mineral Research, 28, 780–793. doi: 10.1002/jbmr.1815.
55. Cho HJ, Jun HJ, Lee JH, Jia Y, Hoang MH, Shim JH, Park KH and Lee SJ, 2012. Acute effect of high-dose isoflavones from Pueraria lobata (Willd.) Ohwi on lipid and bone metabolism in ovariectomized mice. Phytotherapy Research, 26, 1864–1871. doi: 10.1002/ptr.4669.
56. Chung HJ, Chung MJ, Houng S-J, Jeun J, Kweon D-K, Choi C, Park J-T, Park K-H, Lee S-J, 2009. Toxicological evaluation of the isoflavone puerarin and its glycosides. European Food Research and Technology, 230, 145–153.
57. Clarke DB, Barnes KA, Castle L, Rose M, Wilson LA, Baxter MJ, Price KR and DuPont MS, 2003. Levels of phytoestrogens, inorganic trace-elements, natural toxicants and nitrate in vegetarian duplicate diets. Food Chemistry, 81, 287–300.
58. Clarke DB and Lloyd AS, 2004. Dietary exposure estimates of isoflavones from the 1998 UK Total Diet Study. Food Additives and Contaminants, 21, 305–316.
59. Clarke DB, Barnes KA and Lloyd AS, 2004. Determination of unusual soya and non-soya phytoestrogen sources in beer, fish products and other foods. Food Additives and Contaminants, 21, 949–962.
60. Clarke DB, Bailey V and Lloyd AS, 2008. Determination of phytoestrogens in dietary supplements by LC-MS/MS. Food Additives and Contaminants. Part A Chemistry, Analysis, Control, Exposure and Risk Assessment, 25, 534–547. doi: 10.1080/02652030701658340.
61. Clarke DB, Lloyd AS, Lawrence JM, Brown JE, Storey L, Raats M, Rainsbury RM, Culliford DJ, Bailey-Horne VA and Parry BM, 2013. Development of a food compositional database for the estimation of dietary intake of phyto-oestrogens in a group of postmenopausal women previously treated for breast cancer and validation with urinary excretion. British Journal of Nutrition, 109, 2261–2268. doi: 10.1017/S0007114512004394.
62. Colacurci N, De Franciscis P, Atlante M, Mancino P, Monti M, Volpini G and Benvenuti C, 2013. Endometrial, breast and liver safety of soy isoflavones plus Lactobacillus sporogenes in post-menopausal women. Gynecological Endocrinology, 29, 209–212. doi: 10.3109/09513590.2012.738724.
63. Coldham NG and Sauer MJ, 2000. Pharmacokinetics of [14C]genistein in the rat: gender-related differences, potential mechanisms of biological action, and implications for human health. Toxicology and Applied Pharmacology, 164, 206–215.
64. Coldham NG, Zhang AQ, Key P and Sauer MJ, 2002. Absolute bioavailability of [14C] genistein in the rat; plasma pharmacokinetics of parent compound, genistein glucuronide and total radioactivity. European Journal of Drug Metabolism and Pharmacokinetics, 27, 249–258.
65. Conrad SC, Chiu H and Silverman BL, 2004. Soy formula complicates management of congenital hypothyroidism. Archives of Disease in Childhood, 89, 37–40.
66. COT (Committee on Toxicity of Chemicals in Food, Consumer Products and the Environment), 2003, online. Phytoestrogens and health. Available online: http://cot.food.gov.uk/sites/default/files/cot/phytoreport0503.pdf.
67. COT (Committee on Toxicity of Chemicals in Food, Consumer Products and the Environment), 2012, online. COT statement on the FSA phytoestrogens research programme Available online: http://cot.food.gov.uk/committee/committee-on-toxicity/cotstatements/cotstatementsyrs/cotstatements2012/cot201201.
68. Csupor D, Bognár J and Karsai J, 2015. An optimized method for the quantification of isoflavones in dry soy extract containing products. Food Analytical Methods, 8, 2515–2523. doi: 10.1007/s12161-015-0143-5.
69. Delmanto A, Nahas-Neto J, Traiman P, Uemura G, Pessoa EC and Nahas EA, 2013. Effects of soy isoflavones on mammographic density and breast parenchyma in postmenopausal women: a randomized, double-blind, placebo-controlled clinical trial. Menopause, 20, 1049–1054. doi: 10.1097/GME.0b013e3182850270.
70. Diaz Brinton R, 2012. Minireview: translational animal models of human menopause: challenges and emerging opportunities. Endocrinology, 153, 3571–3578. doi: 10.1210/en.2012-1340.
71. Di Virgilio AL, Iwami K, Wätjen W, Kahl R and Degen GH, 2004. Genotoxicity of the isoflavones genistein, daidzein and equol in V79 cells. Toxicology Letters, 151, 151–162.
72. Doerge DR and Sheehan DM, 2002. Goitrogenic and estrogenic activity of soy isoflavones. Environmental Health Perspectives, 110, 349–353.
73. Dong XL, Cao SS, Gao QG, Feng HT, Wong MS and Denney L, 2014. Combination treatment with Fructus Ligustri Lucidi and Puerariae radix offsets their independent actions on bone and mineral metabolism in ovariectomized rats. Menopause, 21, 286–294. doi: 10.1097/GME.0b013e3182966fd3.
74. Duncan AM, Underhill KE, Xu X, Lavalleur J, Phipps WR and Kurzer MS, 1999. Modest hormonal effects of soy isoflavones in postmenopausal women. The Journal of Clinical Endocrinology and Metabolism, 84, 3479–3484.
75. EFSA (European Food Safety Authority), 2011a. Evaluation of the FoodEx, the food classification system applied to the development of the EFSA Comprehensive European Food Consumption Database. EFSA Journal 2011;9 (3):1970, 27 pp. doi:10.2903/j.efsa.2011.1970.
76. EFSA (European Food Safety Authority), 2011b. Use of the EFSA Comprehensive European Food Consumption Database in Exposure Assessment. EFSA Journal 2011;9 (3):2097, 34 pp. doi:10.2903/j.efsa.2011.2097.
77. EFSA (European Food Safety Authority), 2012. Compendium of botanicals reported to contain naturally occurring substances of possible concern for human health when used in food and food supplements. EFSA Journal, 2012;10 (5): 2663. 60 pp. doi:10.2903/j.efsa.2012.2663.
78. EFSA Panel on Dietetic Products, Nutrition and Allergies (NDA), 2009. Scientific Opinion on the substantiation of health claims related to soy isoflavones and maintenance of bone mineral density (ID 1655) pursuant to Article 13(1) of Regulation (EC) No 1924/2006 on request from the European Commission. EFSA Journal 2009; 7 (9): 1270, 14 pp. doi:10.2903/j.efsa.2009.1270.
79. EFSA Panel on Dietetic Products, Nutrition and Allergies (NDA), 2010a. Scientific Opinion on the substantiation of a health claim related to soy protein and reduction of blood cholesterol concentrations pursuant to Article 14 of the Regulation (EC) No 1924/2006. EFSA Journal 2010; 8 (7): 1688, 14 pp. doi:10.2903/j.efsa.2010.1688.
80. EFSA Panel on Dietetic Products, Nutrition and Allergies (NDA), 2010b. Scientific Opinion on the substantiation of health claims related to soy protein and contribution to the maintenance or achievement of a normal body weight (ID 598), maintenance of normal blood cholesterol concentrations (ID 556) and protection of DNA, proteins and lipids from oxidative damage (ID 435) pursuant to Article 13(1) of Regulation (EC) No 1924/2006. EFSA Journal 2010;8 (10): 1812, 17 pp. doi:10.2903/j.efsa.2010.1812.
81. EFSA Panel on Dietetic Products, Nutrition and Allergies (NDA), 2011a. Scientific Opinion on the substantiation of health claims related to soy isoflavones and protection of DNA, proteins and lipids from oxidative damage (ID 1286, 4245), maintenance of normal blood LDL-cholesterol concentrations (ID 1135, 1704a, 3093a), reduction of vasomotor symptoms associated with menopause (ID 1654, 1704b, 2140, 3093b, 3154, 3590), maintenance of normal skin tonicity (ID 1704a), contribution to normal hair growth (ID 1704a, 4254), ¡°cardiovascular health¡± (ID 3587), treatment of prostate cancer (ID 3588), and ¡°upper respiratory tract¡± (ID 3589) pursuant to Article 13(1) of Regulation (EC) No 1924/2006. EFSA Journal 2011;9 (7): 2264, 44 pp. doi:10.2903/j.efsa.2011.2264.
82. EFSA Panel on Dietetic Products, Nutrition and Allergies (NDA), 2011b. Scientific Opinion on the safety of ¡°fermented black bean extract (Touchi). as a Novel Food Ingredient. EFSA Journal 2011;9 (5): 2136, 20 pp. doi:10.2903/j.efsa.2011.2136.
83. EFSA Panel on Dietetic Products, Nutrition and Allergies (NDA), 2012a. Scientific Opinion on the substantiation of health claims related to soy isoflavones and maintenance of bone mineral density (ID 1655) and reduction of vasomotor symptoms associated with menopause (ID 1654, 1704, 2140, 3093, 3154, 3590) (further assessment) pursuant to Article 13(1) of Regulation (EC) No 1924/2006. EFSA Journal 2012;10 (8): 2847, 36 pp. doi:10.2903/j.efsa.2012.2847.
84. EFSA Panel on Dietetic Products, Nutrition and Allergies (NDA), 2012b. Scientific Opinion on the substantiation of a health claim related to isolated soy protein and reduction of blood LDL-cholesterol concentrations pursuant to Article 14 of Regulation (EC) No 1924/2006. EFSA Journal 2012;10 (2): 2555, 17 pp. doi:10.2903/j.efsa.2012.2555.
85. EFSA Scientific Committee (SC), 2012. Guidance on selected default values to be used by the EFSA Scientific Committee, Scientific Panels and Units in the absence of actual measured data. EFSA Journal 2012;10 (3): 2579, 32 pp.doi:10.2903/j.efsa.2012.2579.
86. Evans M, Elliott JG, Sharma P, Berman R and Guthrie N, 2011. The effect of synthetic genistein on menopause symptom management in healthy postmenopausal women: a multi-center, randomized, placebo-controlled study. Maturitas, 68, 189. 196. doi: 10.1016/j.maturitas.2010.11.012.
87. Fiechter G, Raba B, Jungmayr A and Mayer HK, 2010. Characterisation of isoflavone composition in soy-based nutritional supplements via ultra performance liquid chromatography. Analytica Chimica Acta, 672, 72. 78. doi:10.1016/j.aca.2010.04.004.
88. Foth D and Cline JM, 1998. Effects of mammalian and plant estrogens on mammary glands and uteri of macaques. American Journal of Clinical Nutrition, 68, 1413S–1417S.
89. Foth D and Nawroth F, 2005. Effect of phytoestrogens on the endometrium? Fertility and Sterility, 83, 256–257. doi: http://dx.doi.org/10.1016/j.fertnstert.2004.10.021.
90. Fotsis T, Pepper M, Adlercreutz H, Fleischmann G, Hase T, Montesano R and Schweigerer L, 1993. Genistein, a dietary-derived inhibitor of in vitro angiogenesis. Proceedings of the National Academy of Sciences of the United States of America, 90, 2690–2694.
91. Francisco AM, Carbonel AF, Simões RS, Soares JM Jr, Baracat EC and Haidar MA, 2013. Do extracts of oral soybean augment the trophic effect of estrogen on the rat uterus? Climacteric, 16, 161–168. doi: 10.3109/13697137.2012.679168.
92. Fritz H, Seely D, Flower G, Skidmore B, Fernandes R, Vadeboncoeur S, Kennedy D, Cooley K, Wong R, Sagar S, Sabri E and Fergusson D, 2013. Soy, red clover, and isoflavones and breast cancer: a systematic review. PLoS One, 8, e81968. doi: 10.1371/journal.pone.0081968.
93. Fruzza AG, Demeterco-Berggren C and Jones KL, 2012. Unawareness of the effects of soy intake on the management of congenital hypothyroidism. Pediatrics, 130, e699–702. doi: 10.1542/peds.2011-3350.
94. Gallo D, Zannoni GF, Apollonio P, Martinelli E, Ferlini C, Passetti G, Riva A, Morazzoni P, Bombardelli E and Scambia G, 2005. Characterisation of the pharmacologic profile of a standardized soy extract in the ovariectomized rat model of menopause: effects on bone, uterus, and lipid profile. Menopause, 12, 589–600.
95. Gallo D, Zannoni GF, Martinelli E, Ferlini C, Fabrizi M, Riva A, Morazzoni P, Bombardelli E and Scambia G, 2006. Estradiol and phytoestrogens differently influence the rodent postmenopausal mammary gland. Menopause, 13, 72–79.
96. Gallo D, Zannoni GF, Fabrizi M, De Stefano I, Mantuano E and Scambia G, 2008. Comparative effects of 17beta-estradiol and phytoestrogens in the regulation of endometrial functions in the rodent uterus. Journal of Endocrinological Investigation, 31, 48–56.
97. Gardner CD, Chatterjee LM and Franke AA, 2009. Effects of isoflavone supplements vs. soy foods on blood concentrations of genistein and daidzein in adults. The Journal of Nutritional Biochemistry, 20, 227–234. doi: 10.1016/j.jnutbio.2008.02.008.
98. Geller SE, Shulman LP, Van Breemen RB, Banuvar S, Zhou Y, Epstein G, Hedayat S, Nikolic D, Krause EC, Piersen CE, Bolton JL, Pauli GF and Farnsworth NR, 2009. Safety and efficacy of black cohosh and red clover for the management of vasomotor symptoms: a randomized controlled trial. Menopause, 16, 1156–1166. doi: 10.1097/gme.0b013e3181ace49b.
99. Gründker C, Günthert AR and Emons G, 2008. Hormonal heterogeneity of endometrial cancer. Innovative Endocrinology of Cancer Advances in Experimental Medicine and Biology, 630, 166–188.
100. Gu L, House SE, Prior RL, Fang N, Ronis MJ, Clarkson TB, Wilson ME and Badger TM, 2006. Metabolic phenotype of isoflavones differ among female rats, pigs, monkeys, and women. The Journal of Nutrition, 136, 1215–1221.
101. Gutendorf B and Westendorf J, 2001. Comparison of an array of in vitro assays for the assessment of the estrogenic potential of natural and synthetic estrogens, phytoestrogens and xenoestrogens. Toxicology, 166, 79–89.
102. György P, Murata K and Ikehata H, 1964. Antioxidants isolated from fermented soybeans (tempeh). Nature, 22, 870–872.
103. Hale GE, Hughes CL, Robboy SJ, Agarwal SK and Bievre M, 2001. A double-blind randomized study on the effects of red clover isoflavones on the endometrium. Menopause, 8, 338–346.
104. Han KK, Soares JM Jr, Haidar MA, De Lima GR and Baracat EC, 2002. Benefits of soy isoflavone therapeutic regimen on menopausal symptoms. Obstetrics and Gynecology, 99, 389–394.
105. Harris RM, Wood DM, Bottomley L, Blagg S, Owen K, Hughes PJ, Waring RH and Kirk CJ, 2004. Phytoestrogens are potent inhibitors of estrogen sulfation: implications for breast cancer risk and treatment. Journal of Clinical Endocrinology and Metabolism, 89, 1779–1787.
106. Hargreaves DF, Potten CS, Harding C, Shaw LE, Morton MS, Roberts SA, Howell A and Bundred NJ, 1999. Two-week dietary soy supplementation has an estrogenic effect on normal premenopausal breast. The Journal of Clinical Endocrinology and Metabolism, 84, 4017–4024.
107. Heald CL, Bolton-Smith C, Ritchie MR, Morton MS and Alexander FE, 2006. Phyto-oestrogen intake in Scottish men: use of serum to validate a self-administered food-frequency questionnaire in older men. European Journal of Clinical Nutrition, 60, 129–135.
108. Health Canada, 2009, online. Monograph for soy extract, soy protein isolate and genistein. Available online: http://webprod.hc-sc.gc.ca/nhpid-bdipsn/atReq.do?atid=soy_extra_isolate&lang=eng.
109. Health Canada, 2015a, online. Monograph for red clover. Available online: http://webprod.hc-sc.gc.ca/nhpid-bdipsn/atReq.do?atid=rcie&lang=eng.
110. Health Canada, 2015b, online. Traditional Chinese medications. Available online: http://webprod.hc-sc.gc.ca/nhpid-bdipsn/atReq.do?atid=tcm.
111. Hernandez-Elizondo J, Monteagudo C, Murcia MA, Olea N, Olea-Serrano F and Mariscal-Arcas M, 2013. Assessment of the estrogenicity of the diet of a healthy female Spanish population based on its isoflavone content. Food Additives and Contaminants. Part A, Chemistry, Analysis, Control, Exposure and Risk Assessment, 30, 627–633. doi: 10.1080/19440049.2013.775604.
112. Hertrampf T, Schleipen B, Offermanns C, Velders M, Laudenbach U and Diel P, 2009. Comparison of the bone protective effects of an isoflavone-rich diet with dietary and subcutaneous administrations of genistein in ovariectomized rats. Toxicology Letters, 184, 198–203. doi: 10.1016/j.toxlet.2008.11.006.
113. Hidaka S, Okamoto Y, Miyazaki K and Uesugi T, 2003. Evaluation of a soybean product fujiflavone P40 as an antiosteoporotic agent in rats. Phytotherapy Research, 17, 112–119.
114. Hofmann PJ, Schomburg L and Köhrle J, 2009. Interference of endocrine disrupters with thyroid hormone receptor-dependent transactivation. Toxicological Sciences, 110, 125–137. doi: 10.1093/toxsci/kfp086.
115. Hofmeister FJ, Vondrak B and Barbo DM, 1966. The value of the endometrial biopsy. A study of 14,655 office endometrial biopsies. American Journal of Obstetrics and Gynecology, 95, 91–98.
116. Hofseth LJ, Raafat AM, Osuch JR, Pathak DR, Slomski CA and Haslam SZ, 1999. Hormone replacement therapy with estrogen or estrogen plus medroxyprogesterone acetate is associated with increased epithelial proliferation in the normal postmenopausal breast. The Journal of Clinical Endocrinology and Metabolism, 84, 4559–4565.
117. Hong G-E, Mandal PK, Pyun C-W, Choi K, Kim S-K, Han K-H, Fukushima M, Shin H-C and Lee C-H, 2009. Isoflavone aglycone from fermented soy pulp prevents osteoporosis in ovariectomized rats. Asian Journal of Animal and Veterinary Advances, 4, 288–296. doi: 10.3923/ajava.2009.288.296.
118. Hosoda K, Furuta T and Ishii K, 2011. Metabolism and disposition of isoflavone conjugated metabolites in humans after ingestion of kinako. Drug Metabolism and Disposition, 39, 1762–1767. doi: 10.1124/dmd.111.038281.
119. Howes J, Waring M, Huang L and Howes LG, 2002. Long-term pharmacokinetics of an extract of isoflavones from red clover (Trifolium pratense). Journal of Alternative and Complementary Medicine, 8, 135–142.
120. Hsieh CY, Santell RC, Haslam SZ and Helferich WG, 1998. Estrogenic effects of genistein on the growth of estrogen receptor-positive human breast cancer (MCF-7) cells in vitro and in vivo. Cancer Research, 58, 3833–3838.
121. Huybrechts I, Sioen I, Boon PE, Ruprich J, Lafay L, Turrini A, Amiano P, Hirvonen T, De Neve M, Arcella D, Moschandreas J, Westerlund A, Ribas-Barba L, Hilbig A, Papoutsou S, Christensen T, Oltarzewski M, Virtanen S, Rehurkova I, Azpiri M, Sette S, Kersting M, Walkiewicz A, SerraMajem L, Volatier JL, Trolle E, Tornaritis M, Busk L, Kafatos A, Fabiansson S, De Henauw S and Van Klaveren J, 2011. Dietary Exposure Assessments for Children in Europe (the EXPOCHI project): rationale, methods and design. Archives of Public Health, 69, 4. doi: 10.1186/0778-7367-69-4.
122. Imai Y, Tsukahara S, Asada S and Sugimoto Y, 2004. Phytoestrogens/flavonoids reverse breast cancer resistance protein/ABCG2-mediated multidrug resistance. Cancer Research, 64, 4346–4352.
123. Imhof M, Gocan A, Reithmayr F, Lipovac M, Schimitzek C, Chedraui P and Huber J, 2006. Effects of a red clover extract (MF11RCE) on endometrium and sex hormones in postmenopausal women. Maturitas, 55, 76–81.
124. Irace C, Marini H, Bitto A, Altavilla D, Polito F, Adamo EB, Arcoraci V, Minutoli L, Di Benedetto A, Di Vieste G, De Gregorio C, Gnasso A, Corrao S, Licata G and Squadrito F, 2013. Genistein and endothelial function in postmenopausal women with metabolic syndrome. European Journal of Clinical Investigations, 43, 1025–1031. doi: 10.1111/eci.12139.
125. Islam MA, Bekele R, Vanden Berg JH, Kuswanti Y, Thapa O, Soltani S, Van Leeuwen FX, Rietjens IM and Murk AJ, 2015. Deconjugation of soy isoflavone glucuronides needed for estrogenic activity. Toxicology in Vitro, 29, 706–715. doi:10.1016/j.tiv.2015.01.013.
126. Ju YH, Allred CD, Allred KF, Karko KL, Doerge DR and Helferich WG, 2001. Physiological concentrations of dietary genistein dose-dependently stimulate growth of estrogen-dependent human breast cancer (MCF-7) tumors implanted in athymic nude mice. The Journal of Nutrition, 131, 2957–2962.
127. Ju YH, Doerge DR, Allred KF, Allred CD and Helferich WG, 2002. Dietary genistein negates the inhibitory effect of tamoxifen on growth of estrogen-dependent human breast cancer (MCF-7) cells implanted in athymic mice. Cancer Research, 62, 2474–2477.
128. Ju YH, Allred KF, Allred CD and Helferich WG, 2006. Genistein stimulates growth of human breast cancer cells in a novel, postmenopausal animal model, with low plasma estradiol concentrations. Carcinogenesis, 27, 1292–1299.
129. Ju YH, Doerge DR, Woodling KA, Hartman JA, Kwak J and Helferich WG, 2008. Dietary genistein negates the inhibitory effect of letrozole on the growth of aromatase-expressing estrogen-dependent human breast cancer cells (MCF-7Ca) in vivo. Carcinogenesis, 29, 2162–2168. doi: 10.1093/carcin/bgn161.
130. Kaari C, Haidar MA, Júnior JM, Nunes MG, Quadros LG, Kemp C, Stavale JN and Baracat EC, 2006. Randomized clinical trial comparing conjugated equine estrogens and isoflavones in postmenopausal women: a pilot study. Maturitas, 53, 49–58.
131. Kakehashi A, Tago Y, Yoshida M, Sokuza Y, Wei M, Fukushima S and Wanibuchi H, 2012. Hormonally active doses of isoflavone aglycones promote mammary and endometrial carcinogenesis and alter the molecular tumor environment in Donryu rats. Toxicological Sciences, 126, 39–51. doi: 10.1093/toxsci/kfs016.
132. Kang SJ, Choi BR, Kim SH, Yi HY, Park HR, Kim DC, Choi SH, Han CH, Park SJ, Song CH, Ku SK and Lee YJ, 2015. Dried pomegranate potentiates anti-osteoporotic and anti-obesity activities of red clover dry extracts in ovariectomized rats. Nutrients, 7, 2622–2647.
133. Kaufmann WK, 1998. Human topoisomerase II function, tyrosine phosphorylation and cell cycle checkpoints. Proceedings of the Society of Experimental Biology and Medicine, 217, 327–334.
134. Kawakita S, Marotta F, Naito Y, Gumaste U, Jain S, Tsuchiya J, Minelli E, 2009. Effect of an isoflavones-containing red clover preparation and alkaline supplementation on bone metabolism in ovariectomized rats. Clinical Interventions in Aging, 4, 91–100.
135. Kayisli UA, Aksu CA, Berkkanoglu M and Arici A, 2002. Estrogenicity of isoflavones on human endometrial stromal and glandular cells. Journal of Clinical Endocrinology and Metabolism, 87, 5539–5544.
136. Khaodhiar L, Ricciotti HA, Li L, Pan W, Schickel M, Zhou J and Blackburn GL, 2008. Daidzein-rich isoflavone aglycones are potentially effective in reducing hot flashes in menopausal women. Menopause, 15, 125–132.
137. Khan SA, Chatterton RT, Michel N, Bryk M, Lee O, Ivancic D, Heinz R, Zalles CM, Helenowski IB, Jovanovic BD, Franke AA, Bosland MC, Wang J, Hansen NM, Bethke KP, Dew A, Coomes M and Bergan RC, 2012. Soy isoflavone supplementation for breast cancer risk reduction: a randomized phase II trial. Cancer Prevention Research, 5, 309–319. doi: 10.1158/1940-6207.CAPR-11-0251.
138. Kikuchi-Hayakawa H, Onodera N, Matsubara S, Yasuda E, Chonan O, Takahashi R, Ishikawa F, 1998. Effects of soy milk and bifidobacterium fermented soy milk on lipid metabolism in aged ovariectomized rats. Bioscience, Biotechnology and Biochemistry, 62, 1688–1692.
139. King RA, 1998. Daidzein conjugates are more bioavailable than genistein conjugates in rats. The American Journal of Clinical Nutrition, 68, 1496S–1499S.
140. King RA and Bursill DB, 1998. Plasma and urinary kinetics of the isoflavones daidzein and genistein after a single soy meal in humans. The American Journal of Clinical Nutrition, 67, 867–872.
141. Kinjo J, Tsuchihashi R, Morito K, Hirose T, Aomori T, Nagao T, Okabe H, Nohara T and Masamune Y, 2004. Interactions of phytoestrogens with estrogen receptors a and b (III). Estrogenic activities of soy isoflavone aglycones and their metabolites isolated from human urine. Biological and Pharmaceutical Bulletin, 27, 185–188.
142. Kishida T, Mizushige T, Ohtsu Y, Ishikawa S, Nagamoto M, Izumi T, Obata A and Ebihara K, 2008. Dietary soy isoflavone-aglycone lowers food intake in female rats with and without ovariectomy. Obesity, 16, 290–297. doi: 10.1038/oby.2007.68.
143. Kobayashi S, Shinohara M, Nagai T and Konishi Y, 2013. Transport mechanisms for soy isoflavones and microbial metabolites dihydrogenistein and dihydrodaidzein across monolayers and membranes. Bioscience, Biotechnology and Biochemistry, 77, 2210–2217.
144. Kuiper GG, Lemmen JG, Carlsson B, Corton JC, Safe SH, Van der Saag PT, Van der Burg B and Gustafsson JA, 1998. Interaction of estrogenic chemicals and phytoestrogens with estrogen receptor beta. Endocrinology, 139, 4252–4263.
145. Kulling SE and Metzler M, 1997. Induction of micronuclei, DNA strand breaks and HPRT mutations in cultured Chinese hamster V79 cells by the phytoestrogen coumoestrol. Food and Chemical Toxicology, 35, 605–613.
146. Kulling SE, Rosenberg B, Jacobs E and Metzler M, 1999. The phytoestrogens coumoestrol and genistein induce structural chromosomal aberrations in cultured human peripheral blood lymphocytes. Archives of Toxicology, 73, 50–54.
147. Kulling SE, Honig DM and Metzler M, 2001. Oxidative metabolism of the soy isoflavones daidzein and genistein in humans in vitro and in vivo. Journal of Agricultural and Food Chemistry, 49, 3024–3033.
148. Kwon Y, 2014. Effect of soy isoflavones on the growth of human breast tumors: findings from preclinical studies. Food Science & Nutrition, 2, 613–622.
149. Langer RD, Pierce JJ, O'Hanlan KA, Johnson SR, Espeland MA, Trabal JF, Barnabei VM, Merino MJ and Scully RE, 1997. Transvaginal ultrasonography compared with endometrial biopsy for the detection of endometrial disease. Postmenopausal Estrogen/Progestin Interventions Trial. New England Journal of Medicine, 337, 1792–1798.
150. Lappe J, Kunz I, Bendik I, Prudence K, Weber P, Recker R and Heaney RP, 2013. Effect of a combination of genistein, polyunsaturated fatty acids and vitamins D3 and K1 on bone mineral density in postmenopausal women: a randomized, placebo-controlled, double-blind pilot study. European Journal of Nutrition, 52, 203–215.
151. Larkin T, Price WE and Astheimer L, 2008. The key importance of soy isoflavone bioavailability to understanding health benefits. Critical Reviews in Food Science and Nutrition, 48, 538–552. doi: 10.1080/10408390701542716.
152. Leclercq G and Jacquot Y, 2014. Interactions of isoflavones and other plant derived estrogens with estrogen receptors for prevention and treatment of breast cancer-considerations concerning related efficacy and safety. The Journal of Steroid Biochemistry and Molecular Biology, 139, 237–244. doi: 10.1016/j.jsbmb.2012.12.010.
153. Lee YB, Lee HJ, Kim KS, Lee JY, Nam SY, Cheon SH and Sohn HS, 2004. Evaluation of the preventive effect of isoflavone extract on bone loss in ovariectomized rats. Bioscience, Biotechnology and Biochemistry, 68, 1040–1045.
154. Legette LL, Martin BR, Shahnazari M, Lee WH, Helferich WG, Qian J, Waters DJ, Arabshahi A, Barnes S, Welch J, Bostwick DG and Weaver CM, 2009. Supplemental dietary racemic equol has modest benefits to bone but has mild uterotropic activity in ovariectomized rats. The Journal of Nutrition, 139, 1908–1913. doi: 10.3945/jn.109.108225.
155. Lehmann L, Esch HL, Wagner J, Rohnstock L and Metzler M, 2005. Estrogenic and genotoxic potential of equol and two hydroxylated metabolites of Daidzein in cultured human Ishikawa cells. Toxicology Letters, 158, 72–86.
156. Lepri SR, Luiz RC, Zanelatto LC, Da Silva PB, Sartori D, Ribeiro LR and Mantovani MS, 2013. Chemoprotective activity of the isoflavones, genistein and daidzein on mutagenicity induced by direct and indirect mutagens in cultured HTC cells. Cytotechnology, 65, 213–222. doi: 10.1007/s10616-012-9476-8.
157. Levis S, Strickman-Stein N, Ganjei-Azar P, Xu P, Doerge DR and Krischer J, 2011. Soy isoflavones in the prevention of menopausal bone loss and menopausal symptoms: a randomized, double-blind trial. Archives of Internal Medicine, 171, 1363–1369. doi: 10.1001/archinternmed.2011.330.
158. Li B and Yu S, 2003. Genistein prevents bone resorption diseases by inhibiting bone resorption and stimulating bone formation. Biological and Pharmaceutical Bulletin, 26, 780–786.
159. Limer JL and Speirs V, 2004. Phyto-oestrogens and breast cancer chemoprevention. Breast Cancer Research, 6, 119–127.
160. Liu K, Ma G, Lv G, Zou Y, Wang W, Liu L, Yan P, Liu Y, Jiang L, Liu Y and Liu Z, 2007. Effects of soybean isoflavone dosage and exercise on the serum markers of bone metabolism in ovariectomized rats. Asia Pacific Journal of Clinical Nutrition, 16, 193–195.
161. López-Lazaro M, Willmore E and Austin CA, 2007. Cells lacking DNA topoisomerase II beta are resistant to genistein. Journal of Natural Products, 70, 763–767.
162. Lu LJ, Grady JJ, Marshall MV, Ramanujam VM and Anderson KE, 1995. Altered time course of urinary daidzein and genistein excretion during chronic soya diet in healthy male subjects. Nutrition and Cancer, 24, 311–323.
163. Lynch A, Harvey J, Aylott M, Nicholas E, Burman M, Siddiqui A, Walker S and Rees R, 2003. Investigations into the concept of a threshold for topoisomerase inhibitor-induced clastogenicity. Mutagenesis, 18, 345–353.
164. Magee PJ, Raschke M, Steiner C, Duffin JG, Pool-Zobel BL, Jokela T, Wahala K and Rowland IR, 2006. Equol: a comparison of the effects of the racemic compound with that of the purified S-enantiomer on the growth, invasion, and DNA integrity of breast and prostate cells in vitro. Nutrition and Cancer, 54, 232–242.
165. Maggiolini M, Vivacqua A, Fasanella G, Recchia AG, Sisci D, Pezzi V, Montanaro D, Musti AM, Picard D and Andò S, 2004. The G protein-coupled receptor GPR30 mediates c-fos up-regulation by 17beta-estradiol and phytoestrogens in breast cancer cells. The Journal of Biological Chemistry, 279, 27008–27016.
166. Manjanatha MG, Shelton S, Bishop ME, Lyn-Cook LE and Aidoo A, 2006. Dietary effects of soy isoflavones daidzein and genistein on 7,12-dimethylbenz[a]anthracene-induced mammary mutagenesis and carcinogenesis in ovariectomized Big Blue transgenic rats. Carcinogenesis, 27, 2555–2564.
167. Marini H, Minutoli L, Polito F, Bitto A, Altavilla D, Atteritano M, Gaudio A, Mazzaferro S, Frisina A, Frisina N, Lubrano C, Bonaiuto M, D'Anna R, Cannata ML, Corrado F, Adamo EB, Wilson S and Squadrito F, 2007. Effects of the phytoestrogen genistein on bone metabolism in osteopenic postmenopausal women: a randomized trial. Annals of Internal Medicine, 146, 839–847.
168. Marini H, Bitto A, Altavilla D, Burnett BP, Polito F, Di Stefano V, Minutoli L, Atteritano M, Levy RM, D'Anna R, Frisina N, Mazzaferro S, Cancellieri F, Cannata ML, Corrado F, Frisina A, Adamo V, Lubrano C, Sansotta C, Marini R, Adamo EB and Squadrito F, 2008. Breast safety and efficacy of genistein aglycone for postmenopausal bone loss: a follow-up study. Journal of Clinical Endocrinology and Metabolism, 93, 4787–4796.
169. Marini H, Polito F, Adamo EB, Bitto A, Squadrito F and Benvenga S, 2012. Update on genistein and thyroid: an overall message of safety. Frontiers in Endocrinology, 3, 94. doi: 10.3389/fendo.2012.00094.
170. Markovits J, Linassier C, Fossé P, Couprie J, Pierre J, Jacquemin-Sablon A, Saucier JM, Le Pecq JB and Larsen AK, 1989. Inhibitory effects of the tyrosine kinase inhibitor genistein on mammalian DNA topoisomerase II. Cancer Research, 49, 5111–5117.
171. Martin PM, Horwitz KB, Ryan DS and McGuire WL, 1978. Phytoestrogen interaction with estrogen receptors in human breast cancer cells. Endocrinology, 103, 1860–1867.
172. Martin LJ and Boyd NF, 2008. Mammographic density. Potential mechanisms of breast cancer risk associated with mammographic density: hypotheses based on epidemiological evidence. Breast Cancer Research, 10, 201. doi: 10.1186/bcr1831.
173. Maskarinec G, Verheus M, Steinberg FM, Amato P, Cramer MK, Lewis RD, Murray MJ, Young RL and Wong WW, 2009. Various doses of soy isoflavones do not modify mammographic density in postmenopausal women. The Journal of Nutrition, 139, 981–986. doi: 10.3945/jn.108.102913.
174. Maskarinec G, Nakamura KL, Woolcott CG, Conroy SM, Byrne C, Nagata C, Ursin G and Vachon CM, 2015. Mammographic density and breast cancer risk by family history in women of white and Asian ancestry. Cancer Causes and Control, 26, 621–626. doi: 10.1007/s10552-015-0551-2.
175. Masuda S, Shimamura Y, Kato T, Yu-Feng T, Iwamoto K and Kinae N, 2012. Change in mutagenic activity of genistein after a nitrite treatment. Bioscience, Biotechnology and Biochemistry, 76, 938–941.
176. Mathey J, Mardon J, Fokialakis N, Puel C, Kati-Coulibaly S, Mitakou S, Bennetau-Pelissero C, Lamothe V, Davicco MJ, Lebecque P, Horcajada MN and Coxam V, 2007. Modulation of soy isoflavones bioavailability and subsequent effects on bone health in ovariectomized rats: the case for equol. Osteoporosis International, 18, 671–679.
177. Maul R and Kulling SE, 2010. Absorption of red clover isoflavones in human subjects: results from a pilot study. The British Journal of Nutrition, 103, 1569–1572. doi: 10.1017/S0007114509993564.
178. McClain RM, Wolz E, Davidovich A and Bausch J, 2006. Genetic toxicity studies with genistein. Food and Chemical Toxicology, 44, 42–55. doi:10.1016/j.fct.2005.06.004.
179. McMichael-Phillips DF, Harding C, Morton M, Roberts SA, Howell A, Potten CS and Bundred NJ, 1998. Effects of soy-protein supplementation on epithelial proliferation in the histologically normal human breast. The American Journal of Clinical Nutrition, 68, 1431S–1435S.
180. Merten C, Ferrari P, Bakker M, Boss A, Hearty A, Leclercq C, Lindtner O, Tlustos C, Verger P, Volatier JL and Arcella D, 2011. Methodological characteristics of the national dietary surveys carried out in the European Union as included in the European Food Safety Authority (EFSA) Comprehensive European Food Consumption Database. Food Additives and Contaminants. Part A, Chemistry, Analysis, Control, Exposure and Risk Assessment, 28, 975–995. doi: 10.1080/19440049.2011.576440.
181. Miltyk W, Craciunescu CN, Fischer L, Jeffcoat RA, Koch MA, Lopaczynski W, Mahoney C, Jeffcoat RA, Crowell J, Paglieri J and Zeisel SH, 2003. Lack of significant genotoxicity of purified soy isoflavones (genistein, daidzein, and glycitein) in 20 patients with prostate cancer. American Journal of Clinical Nutrition, 77, 875–882.
182. Misra RR, Hursting SD, Perkins SN, Sathyamoorthy N, Mirsalis JC, Riccio ES and Crowell JA, 2002. Genotoxicity and carcinogenicity studies of soy isoflavones. International Journal of Toxicology, 21, 277–285.
183. Mizushina Y, Shiomi K, Kuriyama I, Takahashi Y and Yoshida H, 2013. Inhibitory effects of a major soy isoflavone, genistein, on human DNA topoisomerase II activity and cancer cell proliferation. International Journal of Oncology, 43, 1117–1124. doi: 10.3892/ijo.2013.2032.
184. Moher D, Liberati A, Tetzlaff J, Altman DG and the PRISMA Group, 2009. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. PLoS Medicine, 6, e1000097. doi: 10.1371/journal.pmed.1 000097.
185. Morabito N, Crisafulli A, Vergara C, Gaudio A, Lasco A, Frisina N, D'Anna R, Corrado F, Pizzoleo MA, Cincotta M, Altavilla D, Ientile R and Squadrito F, 2002. Effects of genistein and hormone-replacement therapy on bone loss in early postmenopausal women: a randomized double-blind placebo-controlled study. Journal of Bone and Mineral Research, 17, 1904–1912.
186. Morani A, Warner M and Gustafsson J-Å, 2008. Biological functions and clinical implications of oestrogen receptor alfa and beta in epithelial tissues. Journal of Internal Medicine, 264, 128–142.
187. Morris SM, Chen JJ, Domon OE, McGarrity LJ, Bishop ME, Manjanatha MG and Casciano DA, 1998. p53, mutations, and apoptosis in genistein-exposed human lymphoblastoid cells. Mutation Research, 405, 41–56.
188. Mortensen A, Kulling SE, Schwartz H, Rowland I, Ruefer CE, Rimbach G, Cassidy A, Magee P, Millar J, Hall WL, Kramer Birkved F, Sorensen IK and Sontag G, 2009. Analytical and compositional aspects of isoflavones in food and their biological effects. Molecular Nutrition and Food Research, 53, S266–309. doi: 10.1002/mnfr.200800478.
189. Mosquette R, De Jesus Simões M, Da Silva ID, Oshima CT, Oliveira-Filho RM, Haidar MA, Simões RS, Baracat EC and Soares Júnior JM, 2007. The effects of soy extract on the uterus of castrated adult rats. Maturitas, 56, 173–183.
190. Mu H, Bai YH, Wang ST, Zhu ZM and Zhang YW, 2009. Research on antioxidant effects and estrogenic effect of formononetin from Trifolium pratense (red clover). Phytomedicine, 16, 314–319. doi: 10.1016/j.phymed.2008.07.005.
191. Müller L and Kasper P, 2000. Human biological relevance and the use of threshold-arguments in regulatory genotoxicity assessment: experience with pharmaceuticals. Mutation Research, 464, 19–34.
192. Mulligan AA, Welch AA, McTaggart AA, Bhaniani A and Bingham SA, 2007. Intakes and sources of soya foods and isoflavones in a UK population cohort study (EPIC-Norfolk). European Journal of Clinical Nutrition, 61, 248–254.
193. Murray MJ, Meyer WR, Lessey BA, Oi RH, DeWire RE and Fritz MA, 2003. Soy protein isolate with isoflavones does not prevent estradiol-induced endometrial hyperplasia in postmenopausal women: a pilot trial. Menopause, 10, 456–464.
194. Nahas EA, Nahas-Neto J, Orsatti FL, Carvalho EP, Oliveira ML and Dias R, 2007. Efficacy and safety of a soy isoflavone extract in postmenopausal women: a randomized, double-blind, and placebo-controlled study. Maturitas, 58, 249–258.
195. Nakayama Y, Saito Y, Soeda S, Iwamoto E, Ogawa S, Yamagishi N, Kuga T and Yamaguchi N, 2014. Genistein induces cytokinesis failure through RhoA delocalisation and anaphase chromosome bridging. Journal of Cellular Biochemistry, 115, 763–771. DOI: 10.1002/jcb.24720.
196. Nguyen BT, Kararigas G and Jarry H, 2013. Dose-dependent effects of a genistein-enriched diet in the heart of ovariectomized mice. Genes and Nutrition, 8, 383–390. doi: 10.1007/s12263-012-0323-5.
197. Nikander E, Rutanen EM, Nieminen P, Wahlström T, Ylikorkala O and Tiitinen A, 2005. Lack of effect of isoflavonoids on the vagina and endometrium in postmenopausal women. Fertility and Sterility, 83, 137–142.
198. NTP (National Toxicology Program), 2008. Toxicology and carcinogenesis studies of genistein (CAS No. 446-72-0) in Sprague-Dawley rats (feed study). National Toxicology Program Technical Report Series, 545, 1–240.
199. Obi N, Chang-Claude J, Berger J, Braendle W, Slanger T, Schmidt M, Steindorf K, Ahrens W and Flesch-Janys D, 2009. The use of herbal preparations to alleviate climacteric disorders and risk of postmenopausal breast cancer in a German case-control study. Cancer Epidemiology, Biomarkers and Prevention, 18, 2207–2213. doi: 10.1158/1055-9965.EPI-09-0298.
200. OECD (Organisation for Economic Cooperation and Development), 2007, online. Test No. 440: Uterotrophic Bioassay in Rodents: A short-term screening test for oestrogenic properties, OECD Guidelines for the Testing of Chemicals, Section 4, OECD Publishing, Paris. doi: http://dx.doi.org/10.1787/9789264067417-en.
201. Ohno S, Shinoda S, Toyoshima S, Nakazawa H, Makino T and Nakajin S, 2002. Effects of flavonoid phytochemicals on cortisol production and on activities of steroidogenic enzymes in human adrenocortical H295R cells. The Journal of Steroid Biochemistry and Molecular Biology, 80, 355–363. doi:10.1016/S0960-0760(02)00021-3.
202. Ohno S, Nakajima Y, Inoue K, Nakazawa H and Nakajina S, 2003. Genistein administration decreases serum corticosterone and testosterone levels in rats. Life Sciences, 74, 6, 733–742. doi:10.1016/j.lfs.2003.04.006.
203. Osada H, Magae J, Watanabe C and Isono K, 1988. Rapid screening method for inhibitors of protein kinase C. The Journal of Antibiotics, 41, 925–931.
204. Overk CR, Guo J, Chadwick LR, Lantvit DD, Minassi A, Appendino G, Chen SN, Lankin DC, Farnsworth NR, Pauli GF, Van Breemen RB and Bolton JL, 2008. In vivo estrogenic comparisons of Trifolium pratense (red clover) Humulus lupulus (hops), and the pure compounds isoxanthohumol and 8-prenylnaringenin. Chemico-Biological Interaction, 176, 30–39. doi: 10.1016/j.cbi.2008.06.005.
205. Pan Y, Anthony M and Clarkson TB, 1999. Effect of estradiol and soy phytoestrogens on choline acetyltransferase and nerve growth factor mRNAs in the frontal cortex and hippocampus of female rats. Proceedings of the Society for Experimental Biology and Medicine, 221, 118–125.
206. Penetar DM, Teter CJ, Ma Z, Tracy M, Lee DY and Lukas SE, 2006. Pharmacokinetic profile of the isoflavone puerarin after acute and repeated administration of a novel kudzu extract to human volunteers. Journal of Alternative and Complementary Medicine, 12, 543–548.
207. Penotti M, Fabio E, Modena AB, Rinaldi M, Omodei U and Viganó P, 2003. Effect of soy-derived isoflavones on hot flushes, endometrial thickness, and the pulsatility index of the uterine and cerebral arteries. Fertility and Sterility, 79, 1112–1117.
208. Persky VW, Turyk ME, Wang L, Freels S, Chatterton R Jr, Barnes S, Erdman J Jr, Sepkovic DW, Bradlow HL and Potter S, 2002. Effect of soy protein on endogenous hormones in postmenopausal women. The American Journal of Clinical Nutrition, 75, 145–153.
209. Petrie WK, Dennis MK, Hu C, Dai D, Arterburn JB, Smith HO, Hathaway HJ and Prossnitz ER, 2013. G protein-coupled estrogen receptor-selective ligands modulate endometrial tumor growth. Obstetrics and Gynecology International, 2013, 472720. doi: 10.1155/2013/472720.
210. Pfeiffer E, Treiling CR, Hoehle SI and Metzler M, 2005. Isoflavones modulate the glucuronidation of estradiol in human liver microsomes. Carcinogenesis, 26, 2172–2178.
211. Phenol-Explorer. Database on polyphenol content in foods. Available online: http://phenol-explorer.eu/.
212. Phrakonkham P, Chevalier J, Desmetz C, Pinnert MF, Bergès R, Jover E, Davicco MJ, Bennetau-Pelissero C, Coxam V, Artur Y and Canivenc-Lavier MC, 2007. Isoflavonoid-based bone-sparing treatments exert a low activity on reproductive organs and on hepatic metabolism of estradiol in ovariectomized rats. Toxicology and Applied Pharmacology, 224, 105–115.
213. Pike AC, Brzozowski AM, Hubbard RE, Bonn T, Thorsell AG, Engström O, Ljunggren J, Gustafsson JA and Carlquist M, 1999. Structure of the ligand-binding domain of oestrogen receptor beta in the presence of a partial agonist and a full antagonist. The EMBO Journal; 18, 4608–4618.
214. Pop EA, Fischer LM, Coan AD, Gitzinger M, Nakamura J and Zeisel SH, 2008. Effects of a high daily dose of soy isoflavones on DNA damage, apoptosis, and estrogenic outcomes in healthy postmenopausal women: a phase I clinical trial. Menopause, 15, 684–692. doi: 10.1097/gme.0b013e318167b8f2.
215. Powles TJ, Howell A, Evans DG, McCloskey EV, Ashley S, Greenhalgh R, Affen J, Flook LA and Tidy A, 2008. Red clover isoflavones are safe and well tolerated in women with a family history of breast cancer. Menopause International, 14, 6–12. doi: 10.1258/mi.2007.007033.
216. Prasain JK, Peng N, Acosta E, Moore R, Arabshahi A, Meezan E, Barnes S and Wyss JM, 2007. Pharmacokinetic study of puerarin in rat serum by liquid chromatography tandem mass spectrometry. Biomedical Chromatography, 21, 410–414. DOI: 10.1002/bmc.772.
217. Prentice RL, 2014. Postmenopausal hormone therapy and the risks of coronary heart disease, breast cancer, and stroke. Seminars in Reproductive Medicine, 32, 419–425. doi: 10.1055/s-0034-1384624.
218. Quaas AM, Kono N, Mack WJ, Hodis HN, Felix JC, Paulson RJ and Shoupe D, 2013. Effect of isoflavone soy protein supplementation on endometrial thickness, hyperplasia, and endometrial cancer risk in postmenopausal women: a randomized controlled trial. Menopause, 20, 840–844. doi: 10.1097/GME.0b013e3182804353.
219. Rachoñ D, Vortherms T, Seidlova-Wuttke D and Wuttke W, 2007a. Dietary daidzein and puerarin do not affect pituitary LH expression but exert uterotropic effects in ovariectomized rats. Maturitas, 57, 161–170.
220. Rachoñ D, Vortherms T, Seidlová-Wuttke D, Menche A and Wuttke W, 2007b. Uterotropic effects of dietary equol administration in ovariectomized Sprague-Dawley rats. Climacteric, 10, 416–426.
221. Rachoñ D, Menche A, Vortherms T, Seidlová-Wuttke D and Wuttke W, 2008. Effects of dietary equol administration on the mammary gland in ovariectomized Sprague-Dawley rats. Menopause, 15, 340–345.
222. Rafii F, 2015. The role of colonic bacteria in the metabolism of the natural isoflavone daidzin to equol. Metabolites, 5, 56–73. doi: 10.3390/metabo5010056.
223. Rannikko A, Petas A, Rannikko S and Adlercreutz H, 2006. Plasma and prostate phytoestrogen concentrations in prostate cancer patients after oral phytoestogen supplementation. Prostate, 66, 82–87.
224. Rebbeck TR, Troxel AB, Norman S, Bunin GR, DeMichele A, Baumgarten M, Berlin M, Schinnar R and Strom BL, 2007. A retrospective case-control study of the use of hormone-related supplements and association with breast cancer. International Journal of Cancer, 120, 1523–1528.
225. Rietjens IM, Sotoca AM, Vervoort J and Louisse J, 2013. Mechanisms underlying the dualistic mode of action of major soy isoflavones in relation to cell proliferation and cancer risks. Molecular Nutrition & Food Research, 57, 100–113. doi: 10.1002/mnfr.201200439.
226. Rimoldi G, Christoffel J, Seidlova-Wuttke D, Jarry H and Wuttke W, 2007. Effects of chronic genistein treatment in mammary gland, uterus, and vagina. Environmental Health Perspectives, 115, 62–68. doi: 10.1289/ehp.9367.
227. Ritchie MR, Cummings JH, Morton MS, Michael Steel C, Bolton-Smith C and Riches AC, 2006. A newly constructed and validated isoflavone database for the assessment of total genistein and daidzein intake. British Journal of Nutrition, 95, 204–213. doi: http://dx.doi.org/10.1079/BJN20051603.
228. Rowland I, Faughnan M, Hoey L, Wähälä K, Williamson G and Cassidy A, 2003. Bioavailability of phyto-oestrogens. The British Journal of Nutrition, 89, S45–S58.
229. Rüfer CE, Bub A, Möseneder J, Winterhalter P, Stürtz M and Kulling SE, 2008. Pharmacokinetics of the soybean isoflavone daidzein in its aglycone and glucoside form: a randomized, double-blind, crossover study. The American Journal of Clinical Nutrition, 87, 1314–1323.
230. Ryan-Borchers T, Chew B, Park JS, McGuire MK, Fournier LR and Beerman K, 2008. Effects of dietary and supplemental forms of isoflavones on thyroid function in healthy postmenopausal women. Topics in Clinical Nutrition, 23, 13–22. doi: 10.1097/01.TIN.0000312076.38329.55.
231. Salleh N, Helmy MM, Fadila KN and Yeong SO, 2013. Isoflavone genistein induces fluid secretion and morphological changes in the uteri of post-pubertal rats. International Journal of Medical Sciences, 10, 665–675. doi: 10.7150/ijms.5207.
232. Salti GI, Grewal S, Mehta RR, Das Gupta TK, Boddie AW Jr and Constantinou AI, 2000. Genistein induces apoptosis and topoisomerase II-mediated DNA breakage in colon cancer cells. European Journal of Cancer, 36, 796–802.
233. Sammartino A, Di Carlo C, Mandato VD, Bifulco G, Di Stefano M and Nappi C, 2003. Effects of genistein on the endometrium: ultrasonographic evaluation. Gynecological Endocrinology, 17, 45–49.
234. Sampey BP, Lewis TD, Barbier CS, Makowski L and Kaufman DG, 2011. Genistein effects on stromal cells determines epithelial proliferation in endometrial co-cultures. Experimental and Molecular Pathology, 90, 257–263. doi: 10.1016/j.yexmp.2011.01.006.
235. Sanderson JT, Hordijk J, Denison MS, Springsteel MF, Nantz MH and van den Berg M, 2004. Induction and inhibition of aromatase (CYP19) activity by natural and synthetic flavonoid compounds in H295R human adrenocortical carcinoma cells. Toxicological Sciences, 82, 70–79.
236. Santell RC, Chang YC, Nair MG and Helferich WG, 1997. Dietary genistein exerts estrogenic effects upon the uterus, mammary gland and the hypothalamic/pituitary axis in rats. The Journal of Nutrition, 127, 263–269.
237. Santin AP and Furlanetto TW, 2011. Role of estrogen in thyroid function and growth regulation. Journal of Thyroid Research, 2011, 875125. doi: 10.4061/2011/875125.
238. Sathyapalan T, Manuchehri AM, Thatcher NJ, Rigby AS, Chapman T, Kilpatrick ES and Atkin SL, 2011. The effect of soy phytoestrogen supplementation on thyroid status and cardiovascular risk markers in patients with subclinical hypothyroidism: a randomized, double-blind, crossover study. The Journal of Clinical Endocrinology and Metabolism, 96, 1442–1449. doi: http://dx.doi.org/10.1210/jc.2010–2255.
239. Schmitt E, Metzler M, Jonas R, Dekant W and Stopper H, 2003. Genotoxic activity of four metabolites of the soy isoflavone daidzein. Mutation Research, 542, 43–48.
240. Schulz KF, Altman DG, Moher D and CONSORT Group, 2010. CONSORT 2010 Statement: updated guidelines for reporting parallel group randomised trials. The British Medical Journal, 340, c332. doi: 10.1136/bmj.c332.
241. Schwartz JA, Liu G and Brooks SC, 1998. Genistein-mediated attenuation of tamoxifen-induced antagonism from estrogen receptor-regulated genes. Biochemical and Biophysical Research Communications, 253, 38–43.
242. Schwen R, Jackson R and Proudlock R, 2010. Genotoxicity assessment of S-equol in bacterial mutation, chromosomal aberration, and rodent bone marrow micronucleus tests. Food and Chemical Toxicology, 48, 3481–3485. doi: 10.1016/j.fct.2010.09.027.
243. SciFinder® database, online. Available online: http://scifinder.cas.org.
244. Scott LM, Xu X, Veenstra TD, Tooze JA, Wood CE, Register TC, Kock ND and Cline JM, 2008. Past oral contraceptive use and current dietary soy isoflavones influence estrogen metabolism in postmenopausal monkeys (Macaca fascicularis). Cancer Epidemiology, Biomarkers and Prevention, 17, 2594–2602. doi: 10.1158/1055-9965.EPI-08-0278.
245. Setchell KD, 1998. Phytoestrogens: the biochemistry, physiology, and implications for human health of soy isoflavones. The American Journal of Clinical Nutrition, 68, 1333S–1346S.
246. Setchell KD, Brown NM, Desai P, Zimmer-Nechemias L, Wolfe BE, Brashear WT, Kirschner AS, Cassidy A and Heubi JE, 2001. Bioavailability of pure isoflavones in healthy humans and analysis of commercial soy isoflavone supplements. The Journal of Nutrition, 131, 1362S–1375S.
247. Setchell KD, Brown NM, Zimmer-Nechemias L, Brashear WT, Wolfe BE, Kirschner AS and Heubi JE, 2002. Evidence for lack of absorption of soy isoflavone glycosides in humans, supporting the crucial role of intestinal metabolism for bioavailability. American Journal of Clinical Nutrition, 76, 447–453.
248. Setchell KD, Brown NM, Desai PB, Zimmer-Nechimias L, Wolfe B, Jakate AS, Creutzinger V and Heubi JE, 2003a. Bioavailability, disposition, and dose-response effects of soy isoflavones when consumed by healthy women at physiologically typical dietary intakes. The Journal of Nutrition, 133, 1027–1035.
249. Setchell KD, Faughnan MS, Avades T, Zimmer-Nechemias L, Brown NM, Wolfe BE, Brashear WT, Desai P, Oldfield MF, Botting NP and Cassidy A, 2003b. Comparing the pharmacokinetics of daidzein and genistein with the use of 13C-labeled tracers in premenopausal women. The American Journal of Clinical Nutrition, 77, 411–419.
250. Setchell KD, Clerici C, Lephart ED, Cole SJ, Heenan C, Castellani D, Wolfe BE, Nechemias-Zimmer L, Brown NM, Lund TD, Handa RJ and Heubi JE, 2005. S-equol, a potent ligand for estrogen receptor beta, is the exclusive enantiomeric form of the soy isoflavone metabolite produced by human intestinal bacterial flora. The American Journal of Clinical Nutrition, 81, 1072–1079.
251. Setchell KD, Brown NM, Zhao X, Lindley SL, Heubi JE, King EC and Messina MJ, 2011. Soy isoflavone phase II metabolism differs between rodents and humans: implications for the effect on breast cancer risk. The American Journal of Clinical Nutrition, 94, 1284–1294. doi: 10.3945/ajcn.111.019638.
252. Shelnutt SR, Cimino CO, Wiggins PA and Badger TM, 2000. Urinary pharmacokinetics of the glucuronide and sulfate conjugates of genistein and daidzein. Cancer Epidemiology, Biomarkers and Prevention, 9, 413–419.
253. Shelnutt SR, Cimino CO, Wiggins PA, Ronis MJ and Badger TM, 2002. Pharmacokinetics of the glucuronide and sulfate conjugates of genistein and daidzein in men and women after consumption of a soy beverage. The American Journal of Clinical Nutrition, 76, 588–594.
254. Shike M, Doane AS, Russo L, Cabal R, Reis-Filho JS, Gerald W, Cody H, Khanin R, Bromberg J and Norton L, 2014. The effects of soy supplementation on gene expression in breast cancer: a randomized placebo-controlled study. Journal of the National Cancer Institute, 106, p ii: dju189. doi: 10.1093/jnci/dju189.
255. Shinkaruk S, Carreau C, Flouriot G, Bennetau-Pelissero C and Potier M, 2010. Comparative effects of R- and S-equol and implication of transactivation functions (AF-1 and AF-2) in estrogen receptor-induced transcriptional activity. Nutrients, 2, 340–354. doi: 10.3390/nu2030340.
256. Silverstein MG, Kaplan JR, Appt SE, Register TC and Shively CA, 2014. Effect of soy isoflavones on thyroid hormones in intact and ovariectomized cynomolgus monkeys (Macaca fascicularis). Menopause, 21, 1136–1142. doi: 10.1097/GME.0000000000000223.
257. Singh P, Kumar R, Sabapathy SN and Bawa AS, 2008. Functional and edible uses of soy protein products. Comprehensive Reviews in Food Science and Food Safety, 7, 14–28.
258. Snyder RD and Gillies PJ, 2003. Reduction of genistein clastogenicity in Chinese hamster V79 cells by daidzein and other flavonoids. Food and Chemical Toxicology, 41, 1291–1298.
259. Sofuni T, Hayashi M, Nohmi T, Matsuoka A, Yamada M and Kamata E, 2000. Semi-quantitative evaluation of genotoxic activity of chemical substances and evidence for a biological threshold of genotoxic activity. Mutation Research, 464, 97–104.
260. Soukup ST, Al-Maharik N, Botting N and Kulling SE, 2014. Quantification of soy isoflavones and their conjugative metabolites in plasma and urine: an automated and validated UHPLC-MS/MS method for use in large-scale studies. Analytical and Bioanalytical Chemistry, 406, 6007–6020. doi: 10.1007/s00216-014-8034-y.
261. Spagnuolo P, Rasini E, Luini A, Legnaro M, Luzzani M, Casareto E, Carreri M, Paracchini S, Marino F, Cosentino M, 2014. Isoflavone content and estrogenic activity of different batches of red clover (Trifolium pratense L.) extracts: an in vitro study in MCF-7 cells. Fitoterapia, 94, 62–69. doi: 10.1016/j.fitote.2014.01.027.
262. Steinberg FM, Murray MJ, Lewis RD, Cramer MA, Amato P, Young RL, Barnes S, Konzelmann KL, Fischer JG, Ellis KJ, Shypailo RJ, Fraley JK, Smith EO and Wong WW, 2011. Clinical outcomes of a 2-y soy isoflavone supplementation in menopausal women. The American Journal of Clinical Nutrition, 93, 356–367. doi: 10.3945/ajcn.110.008359.
263. Su S-J, Yeh Y-Tand Shyu H-W, 2013. The preventive effect of biochanin a on bone loss in ovariectomized rats: involvement in regulation of growth and activity of osteoblasts and osteoclasts. Evidence-Based Complementary and Alternative Medicine, 2013, Article ID 594857. doi: 10.1155/2013/594857.
264. Suetsugi M, Su L, Karlsberg K, Yuan YC and Chen S, 2003. Flavone and isoflavone phytoestrogens are agonists of estrogen-related receptors. Molecular Cancer Research, 1, 981–991.
265. Tansey G, Hughes CL Jr, Cline JM, Krümmer A, Walmer DK and Schmoltzer S, 1998. Effects of dietary soybean estrogens on the reproductive tract in female rats. Proceedings of the Society for Experimental Biology and Medicine, 217, 340–344.
266. Taxvig C, Elleby A, Sonne-Hansen K, Bonefeld-Jørgensen EC, Vinggaard AM, Lykkesfeldt AE and Nellemann C, 2010. Effects of nutrition relevant mixtures of phytoestrogens on steroidogenesis, aromatase, estrogen, and androgen activity. Nutrition and Cancer, 62, 122–131. doi: 10.1080/01635580903191577.
267. Teixeira CP, Simões RS, Santos MA, Calió ML, Soares JM Jr, Simões MJ, Bertoncini CR, Higa EM and Carbonel AF, 2014. Soybean concentrated extract counteracts oxidative stress in the uterus of rats. Climacteric, 17, 402–409. doi: 10.3109/13697137.2013.856402.
268. Uesugi T, Toda T, Tsuji K and Ishida H, 2001. Comparative study on reduction of bone loss and lipid metabolism abnormality in ovariectomized rats by soy isoflavones, daidzin, genistin, and glycitin. Biological and Pharmaceutical Bulletin, 24, 368–372. doi: 10.1248/bpb.24.368.
269. Ullah MF, Shamim U, Hanif S, Azmi AS and Hadi SM, 2009. Cellular DNA breakage by soy isoflavone genistein and its methylated structural analogue biochanin A. Molecular Nutrition and Food Research, 53, 1376–1385. doi: 10.1002/mnfr.200800547.
270. Umphress ST, Murphy SP, Franke AA, Custer LJ and Blitz CL, 2005. Isoflavone content of foods with soy additives. Journal of Food Composition and Analysis, 18, 533–550. doi:10.1016/j.jfca.2004.04.008.
271. Unfer V, Casini ML, Costabile L, Mignosa M, Gerli S and Di Renzo GC, 2004. Endometrial effects of long-term treatment with phytoestrogens: a randomized, double-blind, placebo-controlled study. Fertility and Sterility, 82, 145–148.
272. Upmalis DH, Lobo R, Bradley L, Warren M, Cone FL and Lamia CA, 2000. Vasomotor symptom relief by soy isoflavone extract tablets in postmenopausal women: a multicenter, double-blind, randomized, placebo-controlled study. Menopause, 7, 236–242.
273. Ursin G and Qureshi SA, 2009. Mammographic density-a useful biomarker for breast cancer risk in epidemiologic studies. Norsk Epidemiologi, 19, 59–68.
274. USDA (United States Department of Agriculture), 2008. Database for the Isoflavone Content of Selected Foods, Release 2.0. Available online: http://www.ars.usda.gov/SP2UserFiles/Place/80400525/Data/isoflav/Isoflav_R2.pdf.
275. Vachon CM, Pankratz VS, Scott CG, Haeberle L, Ziv E, Jensen MR, Brandt KR, Whaley DH, Olson JE, Heusinger K, Hack CC, Jud SM, Beckmann MW, Schulz-Wendtland R, Tice JA, Norman AD, Cunningham JM, Purrington KS, Easton DF, Sellers TA, Kerlikowske K, Fasching PA and Couch FJ, 2015. The contributions of breast density and common genetic variation to breast cancer risk. The Journal of the National Cancer Institute, 107, dju397. doi: 10.1093/jnci/dju397.
276. Valsta LM, Kilkkinen A, Mazur W, Nurmi T, Lampi AM, Ovaskainen ML, Korhonen T, Adlercreutz H and Pietinen P, 2003. Phyto-oestrogen database of foods and average intake in Finland. British Journal of Nutrition, 89, S31–S38.
277. Van der Velpen V, Hollman PC, Van Nielen M, Schouten EG, Mensink M, Van't Veer P and Geelen A, 2014. Large inter-individual variation in isoflavone plasma concentration limits use of isoflavone intake data for risk assessment. European Journal of Clinical Nutrition, 68, 1141–1147; doi:10.1038/ejcn.2014.108.
278. Van Duursen MB, Smeets EE, Rijk JC, Nijmeijer SM and Van den Berg M, 2013. Phytoestrogens in menopausal supplements induce ER-dependent cell proliferation and overcome breast cancer treatment in an in vitro breast cancer model. Toxicology and Applied Pharmacology, 269, 132–40. doi: 10.1016/j.taap.2013.03.014.
279. Van Erp-Baart MA, Brants HA, Kiely M, Mulligan A, Turrini A, Sermoneta C, Kilkkinen A and Valsta LM, 2003. Isoflavone intake in four different European countries: the VENUS approach. British Journal of Nutrition, 89, S25–S30.
280. Velentzis LS, Keshtgar MR, Woodside JV, Leathem AJ, Titcomb A, Perkins KA, Mazurowska M, Anderson V, Wardell K and Cantwell MM, 2011. Significant changes in dietary intake and supplement use after breast cancer diagnosis in a UK multicentre study. Breast Cancer Research and Treatment, 128, 473–482.
281. Vera R, Jiménez R, Lodi F, Sánchez M, Galisteo M, Zarzuelo A, Pérez-Vizcaíno F and Duarte J, 2007. Genistein restores caveolin-1 and AT-1 receptor expression and vascular function in large vessels of ovariectomized hypertensive rats. Menopause, 14, 933–940.
282. Verheus M, Van Gils CH, Kreijkamp-Kaspers S, Kok L, Peeters PHM, Grobbee DE and Van der Schouw YT, 2008. Soy protein containing isoflavones and mammographic density in a randomized controlled trial in postmenopausal women. Cancer Epidemiology, Biomarkers & Prevention, 17, 2632–2638. doi:10.1158/1055-9965.EPI-08-0344.
283. Vergne S, Bennetau-Pelissero C, Lamothe V, Chantre P, Potier M, Asselineau J, Perez P, Durand M, Moore N and Sauvant P, 2008. Higher bioavailability of isoflavones after a single ingestion of a soya-based supplement than a soya-based food in young healthy males. The British Journal of Nutrition, 99, 333–344.
284. Wang TTY, Sathyamoorthy N and Phang JM, 1996. Molecular effects of genistein on estrogen receptors in human breast cancer cells. Carcinogenesis, 17, 271–275.
285. Wang X, Wu J, Chiba H, Umegaki K, Yamada K and Ishimi Y, 2003. Puerariae radix prevents bone loss in ovariectomized mice. Journal of Bone and Mineral Metabolism, 21, 268–275.
286. Wang J, Shang F, Mei Q, Wang J, Zhang R and Wang S, 2008. NO-donating genistein prodrug alleviates bone loss in ovariectomised rats. Swiss Medical Weekly, 138, 602–607. doi: 2008/41/smw-11940.
287. Warming L, Ravn P, Skouby S and Christiansen C, 2002. Measurement precision and normal range of endometrial thickness in a postmenopausal population by transvaginal ultrasound. Ultrasound in Obstetrics and Gynecology, 20, 492–495.
288. Watanabe S, Yamaguchi M, Sobue T, Takahashi T, Miura T, Arai Y, Mazur W, Wähälä K and Adlercreutz H, 1998. Pharmacokinetics of soybean isoflavones in plasma, urine and feces of men after ingestion of 60 g baked soybean powder (kinako). The Journal of Nutrition, 128, 1710–1715.
289. Weiss J, Gibis M, Schuh V and Salminen H, 2010. Advances in ingredient and processing systems for meat and meat products. Meat Science, 86, 196–213. doi: 10.1016/j.meatsci.2010.05.008.
290. Whirledge S, Senbanjo LT and Cidlowski JA, 2015. Genistein disrupts glucocorticoid receptor signalling in human uterine endometrial Ishikawa cells. Environmental Health Perspectives, 123, 80–87. doi: 10.1289/ehp.1408437.
291. Wolfman W, Leyland N, Heywood M, Singh SS, Rittenberg DA, Soucy R, Allaire C, Awadalla A, Best C, Dunn S, Leroux N, Potestio F, Senikas V, Wallace S, Menzies R and Society of Obstetricians and Gynaecologists of Canada, 2010. Asymptomatic endometrial thickening. Journal of Obstetrics and Gynaecology Canada, 32, 990–999.
292. Wood CE, Register TC, Anthony MS, Kock ND and Cline JM, 2004. Breast and uterine effects of soy isoflavones and conjugated equine estrogens in postmenopausal female monkeys. Journal of Clinical Endocrinology and Metabolism, 89, 3462–3468.
293. Wood CE, Appt SE, Clarkson TB, Franke AA, Lees CJ, Doerge DR and Cline JM, 2006. Effects of high-dose soy isoflavones and equol on reproductive tissues in female cynomolgus monkeys. Biology of Reproduction, 75, 477–486. doi: 10.1095/biolreprod.106.052142.
294. Wood CE, Hester JM, Appt SE, Geisinger KR and Cline JM, 2008. Estrogen effects on epithelial proliferation and benign proliferative lesions in the postmenopausal primate mammary gland. Laboratory Investigation, 88, 938–48. doi: 10.1038/labinvest.2008.64.
295. Wuttke W, Rimoldi G, Christoffel J and Seidlova-Wuttke D, 2006. Plant extracts for the treatment of menopausal women: Safe? Maturitas, 55, S92–S100. doi:10.1016/j.maturitas.2006.06.021.
296. Xiao JX, Huang GQ, Geng X and Qiu HW, 2011. Soy-derived isoflavones inhibit HeLa cell growth by inducing apoptosis. Plant Foods for Human Nutrition, 66, 122–128. doi: 10.1007/s11130-011-0224-6.
297. Xu X, Wang HJ, Murphy PA, Cook L and Hendrich S, 1994. Daidzein is a more bioavailable soymilk isoflavone than is genistein in adult women. The Journal of Nutrition, 124, 825–832.
298. Yamaguchi K, Honda H, Wakisaka C, Tohei A and Kogo H, 2001. Effects of phytoestrogens on acetylcholine- and isoprenaline-induced vasodilation in rat aorta. Japanese Journal of Pharmacology, 87, 67–73.
299. Yamashita Y, Kawada S and Nakano H, 1990. Induction of mammalian topoisomerase II dependent DNA cleavage by nonintercalative flavonoids, genistein and orobol. Biochemical Pharmacology, 39, 737–744.
300. Yang Z, Zhu W, Gao S, Xu H, Wu B, Kulkarni K, Singh R, Tang L and Hu M, 2010. Simultaneous determination of genistein and its four phase II metabolites in blood by a sensitive and robust UPLC-MS/MS method: Application to an oral bioavailability study of genistein in mice. Journal of Pharmacological and Biomedical Analysis, 53, 81–89. doi: 10.1016/j.jpba.2010.03.011.
301. Yang Z, Kulkarni K, Zhu W and Hu M, 2012. Bioavailability and pharmacokinetics of genistein: mechanistic studies on its ADME. Anti-cancer Agents in Medicinal Chemistry, 12, 1264–1280.
302. Ye SF, Saga I, Ichimura K, Nagai T, Shinoda M and Matsuzaki S, 2003. Coumestrol as well as isoflavones in soybean extract prevent bone resorption in ovariectomized rats. Endocrine Regulations, 37, 145–152.
303. Yerushalmi R, Woods R, Ravdin PM, Hayes MM and Gelmon KA, 2010. Ki67 in breast cancer: prognostic and predictive potential. The Lancet Oncology, 11, 174–183. doi: 10.1016/S1470-2045(09)70262-1.
304. Yoneda T, Ueno T and Uchiyama S, 2011. S-equol and the fermented soy product SE5-OH containing S-equol similarly decrease ovariectomy-induced increase in rat tail skin temperature in an animal model of hot flushes. Menopause, 18, 814–820. doi: 10.1097/gme.0b013e318208fb0d.
305. Yoon K, Kwack SJ, Kim HS and Lee BM, 2014. Estrogenic endocrine-disrupting chemicals: molecular mechanisms of actions on putative human diseases. Journal of Toxicology and Environmental Health, Part B: Critical Reviews, 17, 127–174. doi: 10.1080/10937404.2014.882194.
306. Yu Z, Gao X, Zhao Y and Bi K, 2007. HPLC determination of safflor yellow A and three active isoflavones from TCM Naodesheng in rat plasma and tissues and its application to pharmacokinetic studies. Biomedical Chromatography, 21, 577–584. doi: 10.1002/bmc.764.
307. Yuan JP, Wang JH and Liu X, 2007. Metabolism of dietary soy isoflavones to equol by human intestinal microflora-implications for health. Molecular Nutrition and Food Research, 51, 765–781.
308. Zamora-Ros R, Knaze V, Luján-Barroso L, Kuhnle GG, Mulligan AA, Touillaud M, Slimani N, Romieu I, Powell N, Tumino R, Peeters PH, De Magistris MS, Ricceri F, Sonestedt E, Drake I, Hjartåker A, Skie G, Mouw T, Wark PA, Romaguera D, Bueno-de-Mesquita HB, Ros M, Molina E, Sieri S, Quirós JR, Huerta JM, Tjønneland A, Halkjær J, Masala G, Teucher B, Kaas R, Travis RC, Dilis V, Benetou V, Trichopoulou A, Amiano P, Ardanaz E, Boeing H, Förster J, Clavel-Chapelon F, Fagherazzi G, Perquier F, Johansson G, Johansson I, Cassidy A, Overvad K and González CA, 2012. Dietary intakes and food sources of phytoestrogens in the European Prospective Investigation into Cancer and Nutrition (EPIC) 24-hour dietary recall cohort. European Journal of Clinical Nutrition, 66, 932–941. doi: 10.1038/ejcn.2012.36.
309. Zeng A, Xing J, Wang C, Song J, Li C, Yang X and Yang G, 2012. Simultaneous analysis and retention behavior of major isoflavonoids in Radix Puerariae lobatae and Radix Puerariae thomsonii by high performance liquid chromatography with cyclodextrins as a mobile phase modifier. Analytica Chimica Acta, 712, 145–151. doi: 10.1016/j.aca.2011.10.061.
310. Zhang R, Wang S, Lu M, Zhang Z, Tian X and Lv D, 2015. Simultaneous determination and pharmacokinetic study of three isoflavones from Trifolium pratense extract in rat plasma by LC-MS/MS. Biomedical Chromatography, 29, 210–219. doi: 10.1002/bmc.3261.
311. Zhang Y, Li Q, Wan HY, Helferich WG and Wong MS, 2009. Genistein and a soy extract differentially affect three-dimensional bone parameters and bone-specific gene expression in ovariectomized mice. Journal of Nutrition, 139, 2230–2236. doi: 10.3945/jn.109.108399.
312. Zhang Z, Lam TN and Zuo Z, 2013. Radix Puerariae: An overview of Its Chemistry, Pharmacology, Pharmacokinetics, and Clinical Use. The Journal of Clinical Pharmacology, 53, 787–811. doi: 10.1002/jcph.96.
313. Zhao L, Mao Z, Schneider LS and Brinton RD, 2011. Estrogen receptor â-selective phytoestrogenic formulation prevents physical and neurological changes in a preclinical model of human menopause. Menopause, 18, 1131–1142. doi: 10.1097/gme.0b013e3182175b66.
314. Zhou S, Hu Y, Zhang B, Teng Z, Gan H, Yang Z, Wang Q, Huan M and Mei Q, 2008. Dose-dependent absorption, metabolism, and excretion of genistein in rats. Journal of Agricultural and Food Chemistry, 56, 8354–8359. doi: 10.1021/jf801051d.
315. Zou S, Du Y and Zhang L, 2012. Genistein Induced hemizygous-type loss of heterozygosity in thymidine kinase gene of L5178Y cells. Journal of Animal and Veterinary Advances, 11, 4655–4659. doi: 10.3923/javaa.2012.4655.4659
316. Boobis AR, Cohen SM, Dellarco V, McGregor D, Meek ME, Vickers C, Willcocks D and Farland W, 2006. IPCS Framework for analyzing the relevance of a cancer mode of action for humans. Critical Reviews in Toxicology, 36, 781–792. doi: 10.1080/10408440600977677.
317. EFSA (European Food Safety Authority), 2005. Opinion of the Scientific Committee on a request from EFSA related to A Harmonised Approach for Risk Assessment of Substances Which are both Genotoxic and Carcinogenic. The EFSA Journal 2005, 282, 1–31. doi: 10.2903/j.efsa.2005.282.
318. EFSA (European Food Safety Authority), 2009. Guidance of the Scientific Committee on a request from EFSA on the use of the benchmark dose approach in risk assessment. The EFSA Journal 2009, 1150, 1–72. doi: 10.2903/j.efsa.2009.1150.
319. EFSA (European Food Safety Authority), 2015. Scientific report on Principles and process for dealing with data and evidence in scientific assessments. EFSA Journal 2015;13 (5): 4121, 35 pp. doi:10.2903/j.efsa.2015.4121.
320. EFSA ANS Panel (EFSA Panel on Food Additives and Nutrient Sources added to Food), 2013a. Scientific Opinion on the evaluation of the safety in use of Yohimbe (Pausinystalia yohimbe (K. Schum.) Pierre ex Beille). EFSA Journal 2013;11 (7): 3302, 46 pp. doi:10.2903/j.efsa.2013.3302.
321. EFSA ANS Panel (EFSA Panel on Food Additives and Nutrient Sources added to Food), 2013b. Scientific Opinion on safety evaluation of Ephedra species in food. EFSA Journal 2013;11 (11): 3467, 79 pp. doi:10.2903/j.efsa.2013.3467.
322. EFSA Panel on Dietetic Products, Nutrition and Allergies (NDA), 2011. Scientific Opinion on the substantiation of health claims related to soy isoflavones and protection of DNA, proteins and lipids from oxidative damage (ID 1286, 4245), maintenance of normal blood LDL-cholesterol concentrations (ID 1135, 1704a, 3093a), reduction of vasomotor symptoms associated with menopause (ID 1654, 1704b, 2140, 3093b, 3154, 3590), maintenance of normal skin tonicity (ID 1704a), contribution to normal hair growth (ID 1704a, 4254), ‘cardiovascular health’ (ID 3587), treatment of prostate cancer (ID 3588), and ‘upper respiratory tract’ (ID 3589) pursuant to Article 13(1) of Regulation (EC) No 1924/2006. EFSA Journal 2011;9 (7): 2264, 44 pp. doi:10.2903/j.efsa.2011.2264.
323. EFSA Panel on Dietetic Products, Nutrition and Allergies (NDA), 2012. Scientific Opinion on the substantiation of health claims related to soy isoflavones and maintenance of bone mineral density (ID 1655) and reduction of vasomotor symptoms associated with menopause (ID 1654, 1704, 2140, 3093, 3154, 3590) (further assessment) pursuant to Article 13(1) of Regulation (EC) No 1924/2006. EFSA Journal 2012;10 (8): 2847, 36 pp. doi:10.2903/j.efsa.2012.2847.
324. Harlow SD, Gass M, Hall JE, Lobo R, Maki P, Rebar RW, Sherman S, Sluss PM, De Villiers TJ and STRAW+10 Collaborative Group, 2012. Executive summary of the Stages of Reproductive Aging Workshop +10: addressing the unfinished agenda of staging reproductive aging. Climacteric, 15, 105–14. doi: 10.3109/13697137.2011.650656.
325. Higgins JPT and Green S (Eds), 2011. Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011. Available online: www.cochrane-handbook.org.
326. Moher D, Liberati A, Tetzlaff J, Altman DG and the PRISMA Group, 2009. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. PLoS Medicine, 6, e1000097. doi: 10.1371/journal.pmed.1000097.
327. NTP OHAT (National Toxicology Program, Office of Health Assessment and Translation), online. Risk of bias rating tool for human and animal studies. Available online: https://ntp.niehs.nih.gov/ntp/ohat/pubs/riskofbiastool_508.pdf.
328. OECD (Organisation for Economic Co-operation and Development), 2007. Test No. 440: Uterotrophic Bioassay in Rodents: A short-term screening test for oestrogenic properties. OECD Guidelines for the Testing of Chemicals, Section 4, OECD Publishing, Paris. doi: http://dx.doi.org/10.1787/9789264067417-en.
329. WHO (World Health Organization), 1996. WHO Scientific Group Research on the menopause in the 1990s. Report from a. WHO Technical Report Series 866. Available online: http://apps.who.int/iris/bitstream/10665/41841/1/WHO_TRS_866.pdf.